Company: APM
Filing Date: 2025-01-03
Form Type: 424B5
Source: 0001213900-25-000606
Chunk: 9

Company: Aptorum Group Ltd
Filing Date: 2025-01-03
Form: 424B5
Chunk 9
---
 Intent and Term Sheet to acquire (“Transaction”) 100% of URF Holding Group Limited and its underlying
businesses (collectively “U Group”). U Group’s major revenue drivers include, but are not limited to, commercial property
rentals, property/premise management, collaborative consumer product sales, innovative consumer brand awareness building, event management,
product promotions and related consulting businesses. Currently, it is contemplated that the Transaction will occur via a reverse takeover
of the Company, which would result in the continued listing of the combined entity on Nasdaq. As consideration for the Transaction, the
Company will issue such number of the Company’s unregistered Class A Ordinary Shares to the shareholders of U Group corresponding
to the higher of (i) the pre-acquisition valuation of the Company or (ii) 15% of the fully diluted capital of the combined business. Upon
the closing of the Transaction, existing shareholders of U Group and the Company will own 85% and 15% of the combined business, respectively.
Subject to the closing of the Transaction, it is contemplated that (but not limited solely to such methods) the Company will distribute
its existing biotechnology businesses and assets in such relevant manner (or such other similar mechanics to the extent permitted by law)
to its pre-acquisition shareholders on a pari-passu basis.

The Transaction is subject
to, among other things, the execution of a mutually agreeable definitive agreement, completion of due diligence, fairness opinions, shareholders’
approvals, if necessary, delivery of relevant financial statements, board of directors and special committee approvals and satisfaction
of all regulatory and Nasdaq approvals, where relevant. There can be no assurance that a definitive agreement will be entered into or
that the proposed transaction will be consummated on the terms set forth herein or at all. Therefore, it is possible that the Transaction
may never occur.

The foregoing is only a brief
description of the Transaction and does not purport to be a complete description of the proposed terms of the Transaction and is qualified
in its entirety by reference to the Term Sheet and the definitive documents, if materialized.

Potential Disposition

On
May 1, 2023, Aptorum Therapeutics Limited, a wholly owned subsidiary of the Company (“Aptorum Therapeutics”), entered into
a non-binding Letter of Intent and Term Sheet regarding the sale (the “Disposition”) of Paths Innovation Limited and its subsidiary,
Paths Diagnostics Pte Ltd. (collectively, the “Targets”) to Universal Sequencing